Search - tctmd.com

Displaying 401 - 420 of 1328

Sort: Relevancy | Date

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Presentation TCT 2019

A Randomized Trial of Short-Course Dual Antiplatelet Therapy vs. Oral Anticoagulation to Prevent Cerebral Embolism After Transcatheter Aortic Valve Implantation

Presenter: Victor Alfonso Dias

September 28, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Final Words

Presenter: Roxana Mehran

September 26, 2019

Presentation TCT 2019

Take Home for Clinicians: DM and STEMI

Presenter: Dominick Angiolillo

September 26, 2019

Presentation TCT 2019

COMPLETE Trial: Focus on STEMI and MVD

Presenter: Shamir Mehta

September 26, 2019

Presentation TCT 2019

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Take Home for Clinicians

Presenter: C. Michael Gibson

September 26, 2019

Presentation TCT 2019

Reconciling Adjudicated Data Within a Global Trial

Presenter: Marco Valgimigli

September 26, 2019

Presentation TCT 2019

Transitioning to Monotherapy in Patients After PCI

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Deep Dive

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Advertisement

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

A Randomized Trial of Short-Course Dual Antiplatelet Therapy vs. Oral Anticoagulation to Prevent Cerebral Embolism After Transcatheter Aortic Valve Implantation

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Final Words

Take Home for Clinicians: DM and STEMI

COMPLETE Trial: Focus on STEMI and MVD

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Take Home for Clinicians

Reconciling Adjudicated Data Within a Global Trial

Transitioning to Monotherapy in Patients After PCI

TWILIGHT: A Deep Dive

Welcome and Introductions

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content